Homozygous mutations in caveolin‐3 cause a severe form of rippling muscle disease

Heterozygous missense mutations in the caveolin‐3 gene (CAV3) cause different muscle disorders. Most patients with CAV3 alterations present with rippling muscle disease (RMD) characterized by signs of increased muscle irritability without muscle weakness. In some patients, CAV3 mutations underlie the progressive limb‐girdle muscular dystrophy type 1C (LGMD1C). Here, we report two unrelated patients with novel homozygous mutations (L86P and A92T) in CAV3. Both presented with a more severe clinical phenotype than usually seen in RMD. Immunohistochemical and immunoblot analyses of muscle biopsies showed a strong reduction of caveolin‐3 in both homozygous RMD patients similar to the findings in heterozygous RMD. Electron microscopy studies showed a nearly complete absence of caveolae in the sarcolemma in all RMD patients analyzed. Additional plasma membrane irregularities (small plasmalemmal discontinuities, subsarcolemmal vacuoles, abnormal papillary projections) were more pronounced in homozygous than in heterozygous RMD patients. A stronger activation of nitric oxide synthase was observed in both homozygous patients compared with heterozygous RMD. Like in LGMD1C, dysferlin immunoreactivity is reduced in RMD but more pronounced in homozygous as compared with heterozygous RMD. Thus, we further extend the phenotypic variability of muscle caveolinopathies by identification of a severe form of RMD associated with homozygous CAV3 mutations. Ann Neurol 2003

[1]  I. Nonaka,et al.  Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy , 2002, Neurology.

[2]  F. Sotgia,et al.  Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. , 2002, The American journal of pathology.

[3]  H. Goebel,et al.  A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation , 2001, Neurology.

[4]  M. Lisanti,et al.  Caveolin-deficient mice: insights into caveolar function human disease. , 2001, The Journal of clinical investigation.

[5]  D. Stephan,et al.  Severe autosomal recessive rippling muscle disease , 2001, Muscle & nerve.

[6]  M. Lisanti,et al.  Caveolae and caveolin-3 in muscular dystrophy. , 2001, Trends in molecular medicine.

[7]  J. Tidball,et al.  A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice , 2001, The Journal of cell biology.

[8]  I. Nonaka,et al.  The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. , 2001, Human molecular genetics.

[9]  M. Nöthen,et al.  Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease , 2001, Nature Genetics.

[10]  J. Engelman,et al.  Caveolin-3 Null Mice Show a Loss of Caveolae, Changes in the Microdomain Distribution of the Dystrophin-Glycoprotein Complex, and T-tubule Abnormalities* , 2001, The Journal of Biological Chemistry.

[11]  A. Engel,et al.  The earliest pathologic alterations in dysferlinopathy , 2001, Neurology.

[12]  L. Kunkel,et al.  Mutations in the caveolin-3 gene: When are they pathogenic? , 2001, American journal of medical genetics.

[13]  Y. Sunada,et al.  Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. , 2001, Human molecular genetics.

[14]  J. Stamler,et al.  Physiology of nitric oxide in skeletal muscle. , 2001, Physiological reviews.

[15]  I. Nonaka,et al.  Caveolin-3 deficiency causes muscle degeneration in mice. , 2000, Human molecular genetics.

[16]  M. Blank,et al.  Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. , 2000, Human molecular genetics.

[17]  F. Zara,et al.  Mutation in the CAV3 gene causes partial caveolin-3 deficiency and persistent elevated levels of serum creatine kinase , 2000, Neurology.

[18]  C. Ansevin Phenotypic variability in rippling muscle disease. , 2000, Neurology.

[19]  F. Zara,et al.  Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. , 2000, Neurology.

[20]  R. Parton,et al.  Membrane microdomains and caveolae. , 1999, Current opinion in cell biology.

[21]  J Vrolijk,et al.  New strategy for multi-colour fluorescence in situ hybridisation: COBRA: COmbined Binary RAtio labelling , 1999, European Journal of Human Genetics.

[22]  L. Kunkel,et al.  Caveolin-3 in muscular dystrophy. , 1998, Human molecular genetics.

[23]  F. Zara,et al.  Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy , 1998, Nature Genetics.

[24]  O. Feron,et al.  Nitric oxide synthases: which, where, how, and why? , 1997, Journal of Clinical Investigation.

[25]  H. Kaminski,et al.  Nitric oxide synthase is concentrated at the skeletal muscle endplate , 1996, Brain Research.

[26]  K. Aldape,et al.  Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy , 1995, Cell.

[27]  T. Torbergsen A FAMILY WITH DOMINANT HEREDITARY MYOTONIA, MUSCULAR HYPERTROPHY, AND INCREASED MUSCULAR IRRITABILITY, DISTINCT FROM MYOTONIA CONGENITA THOMSEN , 1975, Acta neurologica Scandinavica.